We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

48 hedge funds and large institutions have $15.7M invested in Theriva Biologics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

6% less funds holding

Funds holding: 51 → 48 (-3)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

44% less capital invested

Capital invested by funds: $27.9M → $15.7M (-$12.2M)

Holders
48
Holders Change
-3
Holders Change %
-5.88%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
12
Reduced
8
Closed
6
Calls
$2.77M
Puts
–
Net Calls
+$2.77M
Net Calls Change
-$6.98M

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$1.23M
2
6CM
683 Capital Management
New York
+$1.07M
3
VF
Virtu Financial
New York
+$150K
4
Citadel Advisors
Citadel Advisors
Florida
+$131K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$81.2K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.26M
2
EDRH
Edmond de Rothschild Holding
Switzerland
-$345K
3
Millennium Management
Millennium Management
New York
-$200K
4
ECM
Element Capital Management
New York
-$171K
5
Squarepoint
Squarepoint
New York
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$6.73M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.33M +$37.5K +6 +1%
MP
3
MSD Partners
New York
$2.09M – – –
William Blair & Company
4
William Blair & Company
Illinois
$877K +$1.23M +197 New
6CM
5
683 Capital Management
New York
$762K +$1.07M +171 New
BlackRock
6
BlackRock
New York
$681K – – –
Millennium Management
7
Millennium Management
New York
$410K -$200K -32 -26%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$313K +$81.2K +13 +22%
VF
9
Virtu Financial
New York
$152K +$150K +24 +240%
Citadel Advisors
10
Citadel Advisors
Florida
$122K +$131K +21 +300%
LTFS
11
Ladenburg Thalmann Financial Services
Florida
$92K – – –
Creative Planning
12
Creative Planning
Kansas
$89K – – –
UBS Group
13
UBS Group
Switzerland
$88K -$81.2K -13 -39%
Northern Trust
14
Northern Trust
Illinois
$87K – – –
IA
15
IFP Advisors
Florida
$83K – – –
Fisher Asset Management
16
Fisher Asset Management
Washington
$68K – – –
FSA
17
Franklin Street Advisors
North Carolina
$64K +$50K +8 +133%
PPA
18
Parametric Portfolio Associates
Washington
$55K +$6.25K +1 +9%
SBIA
19
Sheaff Brock Investment Advisors
Indiana
$51K -$31.2K -5 -31%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$51K – – –
SAM
21
Scopus Asset Management
New York
$51K – – –
VCM
22
Vivaldi Capital Management
Illinois
$51K +$6.25K +1 +9%
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$49K – – –
WS
24
Wedbush Securities
California
$39K +$18.7K +3 +50%
TSS
25
Two Sigma Securities
New York
$39K +$31.2K +5 +125%
1
2 3

TOVX Hedge Fund Activity: Q4 2017 in Review

48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2017, worth a combined $15.7M — down 44% from $27.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TOVX and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 12 added.

The largest buyer was William Blair & Company, opening a new position worth an estimated $1.23M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.26M sold.

  • 48 institutional investors held Theriva Biologics (TOVX) as of Q4 2017, down from 51 in Q3 2017.
  • Funds reported $15.7M of Theriva Biologics stock for Q4 2017, down 44% quarter-over-quarter.
  • 5 funds opened new Theriva Biologics positions in Q4 2017 and 6 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q4 2017 was William Blair & Company, an estimated $1.23M added.
  • The largest Theriva Biologics seller in Q4 2017 was Alyeska Investment Group, an estimated $1.26M sold.

Based on aggregated 13F filings for Q4 2017.